Loading...
XSHE
300406
Market cap1.05bUSD
Oct 09, Last price  
12.14CNY
1D
1.68%
1Q
8.10%
Jan 2017
-44.79%
IPO
114.11%
Name

Beijing Strong Biotechnologies Inc

Chart & performance

D1W1MN
XSHE:300406 chart
P/E
37.48
P/S
5.25
EPS
0.32
Div yield, %
7.54%
Shrs. gr., 5y
2.11%
Rev. gr., 5y
9.83%
Revenues
1.36b
-18.29%
275,963,544380,144,035444,625,403508,274,278566,201,720667,402,749694,277,362774,178,199840,861,680848,118,4921,599,384,3511,510,871,8831,741,626,6751,658,931,9751,355,507,324
Net income
190m
-64.35%
100,782,568137,009,922180,637,382210,640,922245,043,367271,646,055273,151,413300,665,286331,648,685112,277,113405,651,179389,097,646523,742,831532,635,354189,874,181
CFO
565m
-7.96%
45,898,334125,486,142147,193,672156,938,955142,586,445243,206,450207,907,483256,147,805188,603,373123,058,597341,098,641396,165,883590,149,292614,011,929565,109,750
Dividend
Sep 03, 20260.15 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Beijing Strong Biotechnologies, Inc. operates as a supplier of in-vitro diagnostic (IVD) solutions, encompassing both products and associated services, for markets within the People's Republic of China and globally. The firm's comprehensive product line includes offerings for clinical biochemistry, such as diagnostic reagents and sophisticated automated analyzers. Additionally, it provides coagulation-related items, including necessary reagents and automated analysis instrumentation. Furthermore, its serology division delivers blood type testing cards and advanced automated systems for blood grouping. This enterprise was established in 2001 and has its corporate headquarters situated in Beijing, China.

Key people

Hongjun Liang
Vice Chairman of the Board, General Manager · since 2023
Wei Liu
Chief Financial Officer · since 2007
Qixin Lin
Deputy General Manager · since 2023
Qinghai Yang
Deputy General Manager · since 2023
Yi Zhang
Deputy General Manager · since 2008
Jianmin Wang
Secretary of the Board · since 2015
Xi Liu
Director · since 2023
Aiping Luo
Director · since 2001
Xiaolin Sun
Director · since 2001
Xiaoya Wang
Director · since 2023
Zuojun Zou
Chairman of the Board · since 2011
Independent Director · since 2020
Jianping Yang
Independent Director · since 2023
Jun Ye
Independent Director · since 2023
IPO date
Oct 30, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT